|View printer-friendly version|
|March 03, 2016 8:01 a.m.|
|Teva to Present New Respiratory Data at the 2016 Academy of Allergy, Asthma and Immunology Annual Meeting|
Positive Data Reported For Teva’s Targeted Biologic; and Pediatric Data on Breath-Actuated, Dry-Powder Short-Acting Beta-Agonist (SABA) Inhaler
Teva will present results from several analyses of data from the pivotal Phase III clinical trial program for reslizumab, an investigational humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. The first oral presentation will highlight results from an analysis that examined the effect of reslizumab on clinical asthma exacerbations in patients with chronic sinusitis and/or nasal polyps in addition to inadequately controlled asthma and elevated blood eosinophils. The second oral session will present results from a pooled analysis that evaluated the efficacy of reslizumab in patients aged 65 years and older with asthma and elevated blood eosinophils. The poster presentation will highlight further analysis of quality of life data in patients with inadequately controlled asthma and elevated blood eosinophils treated with reslizumab.
Additional data to be presented include two poster presentations of pediatric data on ProAir RespiClick® (albuterol sulfate) Inhalation Powder, a breath-actuated, multi-dose, dry-powder, short-acting beta-agonist (SABA) inhaler. Among the presentations is a dose-ranging efficacy and safety study in which the treatment was compared to both albuterol hydrofluoroalkane (HFA) Inhalation Aerosol and placebo in pediatric patients (ages 4-11) with asthma.
“The AAAAI Annual Meeting provides Teva with an exciting opportunity to
showcase the important work being done to support our goal of bringing
additional options, such as reslizumab and ProAir RespiClick®,
to asthma patients,” said
The following Teva-sponsored data will be presented at the 2016 AAAAI Annual Meeting:
ProAir® RespiClick (albuterol sulfate) Inhalation Powder
All abstracts have been published in an online supplement to the
February issue of The
About Teva Respiratory
Teva Respiratory develops and delivers high-quality treatment options for respiratory conditions, including asthma, COPD and allergic rhinitis. The Teva Respiratory portfolio is centered on optimizing respiratory treatment for patients and healthcare providers through the development of novel delivery systems and therapies that help address unmet needs. The company’s respiratory pipeline and clinical trial program are based on drug molecules delivered in proprietary dry powder formulations and breath-actuated device technologies, as well as a targeted biologic treatment for severe asthma. Through research and clinical development, Teva Respiratory continually works to expand, strengthen and build upon its treatment portfolio to positively impact the lives of the millions of patients living with respiratory disease.
Reslizumab is an investigational humanized interleukin-5 (IL-5)
antagonist IgG4K monoclonal antibody (mAb), for add-on maintenance
treatment of severe asthma in patients with an eosinophilic phenotype.
IL-5 is the most selective eosinophil cytokine known and plays a major
role in the maturation, activation and survival of eosinophils. In
asthma patients, the eosinophilic phenotype is associated with
compromised lung function, more frequent symptoms, and increased risk of
exacerbations. Reslizumab binds to human IL-5 and prevents it from
binding to the IL-5 receptor, thereby reducing eosinophilic
inflammation. Reslizumab has been submitted to and is currently under
review by the
About ProAir® RespiClick (albuterol sulfate) Inhalation Powder
ProAir® RespiClick (albuterol sulfate) Inhalation Powder is indicated in patients 12 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Important Safety Information
Teva Pharmaceutical Industries Ltd.